DNMT3A and angioimmunoblastic T-cell lymphoma: For example, DNMT3A is overexpressed in 30% of angioimmunoblastic T-cell lymphoma (AITL) and 40% of DLBCL and is associated with reduced overall survival (OS) and event-free survival (EFS) in DLBCL patients (26).